CN110831936B - 具有dub抑制剂活性的取代氰基吡咯烷 - Google Patents

具有dub抑制剂活性的取代氰基吡咯烷 Download PDF

Info

Publication number
CN110831936B
CN110831936B CN201880040925.5A CN201880040925A CN110831936B CN 110831936 B CN110831936 B CN 110831936B CN 201880040925 A CN201880040925 A CN 201880040925A CN 110831936 B CN110831936 B CN 110831936B
Authority
CN
China
Prior art keywords
methyl
triazole
carboxamide
alkyl
cyanophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880040925.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN110831936A (zh
Inventor
M·L·斯托克利
M·I·肯普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mission Therapeutics Ltd
Original Assignee
Mission Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1709824.5A external-priority patent/GB201709824D0/en
Priority claimed from GBGB1803561.8A external-priority patent/GB201803561D0/en
Application filed by Mission Therapeutics Ltd filed Critical Mission Therapeutics Ltd
Publication of CN110831936A publication Critical patent/CN110831936A/zh
Application granted granted Critical
Publication of CN110831936B publication Critical patent/CN110831936B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880040925.5A 2017-06-20 2018-06-19 具有dub抑制剂活性的取代氰基吡咯烷 Active CN110831936B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1709824.5 2017-06-20
GBGB1709824.5A GB201709824D0 (en) 2017-06-20 2017-06-20 Novel Compounds
GBGB1803561.8A GB201803561D0 (en) 2018-03-06 2018-03-06 Novel compounds
GB1803561.8 2018-03-06
PCT/GB2018/051691 WO2018234775A1 (en) 2017-06-20 2018-06-19 Substituted cyanopyrrolidines with activity as dub inhibitors

Publications (2)

Publication Number Publication Date
CN110831936A CN110831936A (zh) 2020-02-21
CN110831936B true CN110831936B (zh) 2023-03-28

Family

ID=62778943

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880040925.5A Active CN110831936B (zh) 2017-06-20 2018-06-19 具有dub抑制剂活性的取代氰基吡咯烷

Country Status (5)

Country Link
US (1) US11059809B2 (https=)
EP (1) EP3642196B1 (https=)
JP (1) JP7208931B2 (https=)
CN (1) CN110831936B (https=)
WO (1) WO2018234775A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522267D0 (en) * 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
ES2850349T3 (es) 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
BR112020003725A2 (pt) 2017-10-06 2020-11-03 Forma Therapeutics, Inc. inibição da peptidase 30 específica de ubiquitina
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
LT3860989T (lt) 2018-10-05 2023-06-12 Forma Therapeutics, Inc. Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
US20250034122A1 (en) 2021-12-01 2025-01-30 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
WO2023149768A1 (ko) * 2022-02-07 2023-08-10 주식회사 내쉬원 탈유비퀴틴화효소 억제제를 포함하는 소포체 스트레스 관련 질환 예방 또는 치료용 약학적 조성물
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046530A1 (en) * 2014-09-23 2016-03-31 Mission Therapeutics Ltd Novel compounds
WO2016156816A1 (en) * 2015-03-30 2016-10-06 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
WO2017103614A1 (en) * 2015-12-17 2017-06-22 Mission Therapeutics Limited Novel Compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077073A1 (en) 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
PE20090606A1 (es) 2007-08-20 2009-06-17 Glaxo Group Ltd Nuevos inhibidores de catepsina c y uso
PE20091843A1 (es) 2008-04-18 2010-01-07 Glaxo Group Ltd Inhibidores de catepsina c
TW201002318A (en) 2008-04-18 2010-01-16 Glaxo Group Ltd Cathepsin C inhibitors
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
CA2918242C (en) 2013-07-31 2022-06-21 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
US9963444B2 (en) 2014-05-19 2018-05-08 Northeastern University N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof
WO2015183987A1 (en) * 2014-05-27 2015-12-03 Pharmakea, Inc. Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US10669234B2 (en) 2015-07-14 2020-06-02 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
JP6959252B2 (ja) 2016-03-24 2021-11-02 ミッション セラピューティクス リミティド Ｄｕｂ阻害剤としての１−シアノピロリジン誘導体
ES2850349T3 (es) 2016-09-27 2021-08-27 Mission Therapeutics Ltd Derivados de cianopirrolidina con actividad como inhibidores de USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016046530A1 (en) * 2014-09-23 2016-03-31 Mission Therapeutics Ltd Novel compounds
WO2016156816A1 (en) * 2015-03-30 2016-10-06 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
WO2017103614A1 (en) * 2015-12-17 2017-06-22 Mission Therapeutics Limited Novel Compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY;registry;《STN》;20161129;1-6 *

Also Published As

Publication number Publication date
JP7208931B2 (ja) 2023-01-19
US20200172519A1 (en) 2020-06-04
EP3642196A1 (en) 2020-04-29
JP2020524166A (ja) 2020-08-13
WO2018234775A1 (en) 2018-12-27
EP3642196B1 (en) 2022-08-17
CN110831936A (zh) 2020-02-21
US11059809B2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
CN110831936B (zh) 具有dub抑制剂活性的取代氰基吡咯烷
US11958833B2 (en) Compounds
EP3416960B1 (en) Novel compounds
EP3519412B1 (en) Cyanopyrrolidine derivatives with activity as inhibitors of usp30
TWI766882B (zh) 新穎化合物類
US11370784B2 (en) Cyano-substituted heterocycles with activity as inhibitors of USP30
US11014912B2 (en) Cyanopyrrolidine derivatives with activity as inhibitors of USP30
AU2016384921B2 (en) Crystalline form of BTK kinase inhibitor and preparation method thereof
WO2019171042A1 (en) Cyanopyrrolidines as usp30 inhibitors and fibrosis treatment
JP7796047B2 (ja) Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン
MD4161929T2 (ro) 1-(5-(2-Cianopiridin-4-il)oxazol-2-carbonil)-4-metilhexahidropirolo[3,4-b]pirol-5(1H)-carbonitril în calitate de inhibitor al USP30 pentru utilizare în tratamentul disfuncției mitocondriale al cancerului și al fibrozei
EP4364737A2 (en) Triazolopyridinyl compounds as kinase inhibitors
JP2024544660A (ja) Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン
WO2025262433A1 (en) N-cyanopyrrolidines with activity as usp30 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant